LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.
The Valeda system has received a CE mark in Europe for the treatment of ocular diseases including dry age-related macular degeneration. The new studies in diabetic retinopathy will take place with the University of Wisconsin-Milwaukee.
“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with [photobiomodulation],” Janis Eells, PhD, professor, University of Wisconsin-Milwaukee, said in the release. “Our work shows that early [photobiomodulation] benefits in reducing the detrimental effects of high glucose on retinal cells, and early human data is now starting to show benefits in the clinical setting.”